Vol 8, Supp. A (2017)
Case report
Published online: 2017-12-21
Pomalidomide in combination with clarithromycin and dexamethasone for double refractory plasma cell myeloma — a case report and review of literature
Abstract
Pomalidomide is a new immunomodulatory drug used for treatment of plasma cell myeloma (PCM). In this paper, we describe a case report of a woman with PCM who was double refractory to bortezomib and lenalidomide, and was subsequently treated with pomalidomide with clarithromycin and dexamethasone.
Keywords: refractory plasma cell myelomapomalidomide